<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>Annals of Internal Medicine: Liver Cancer Topic Collection</title>
    <link>http://annals.org/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Tue, 05 Mar 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 09 Apr 2013 13:47:24 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@annals.org</managingEditor>
    <webMaster>webmaster@annals.org</webMaster>
    <item>
      <title>Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma A Meta-analysis of Observational Studies </title>
      <link>http://annals.org/article.aspx?articleID=1657880</link>
      <pubDate>Tue, 05 Mar 2013 00:00:00 GMT</pubDate>
      <author>Morgan RL, Baack B, Smith BD, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Background:&lt;/div&gt;Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC). In the United States, this form of cancer occurs in approximately 15 000 persons annually. A systematic review of the evidence is needed to assess the benefits of treatment of HCV-infected persons on development of HCC.&lt;div class="boxTitle"&gt;Purpose:&lt;/div&gt;To systematically review observational studies to determine the association between response to HCV therapy and development of HCC among persons at any stage of fibrosis and those with advanced liver disease.&lt;div class="boxTitle"&gt;Data Sources:&lt;/div&gt;MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science, and the Database of Abstracts of Reviews and Effectiveness from inception through February 2012.&lt;div class="boxTitle"&gt;Study Selection:&lt;/div&gt;English-language observational studies that compared therapy-derived sustained virologic response (SVR) with no response to therapy among HCV-infected persons, targeted an adult population, and had an average follow-up of at least 2 years.&lt;div class="boxTitle"&gt;Data Extraction:&lt;/div&gt;Two investigators independently extracted data into uniform relative risk measures. The Grading of Recommendations Assessment, Development and Evaluation framework was used to determine the quality of the evidence.&lt;div class="boxTitle"&gt;Data Synthesis:&lt;/div&gt;Thirty studies fulfilled the inclusion criteria, and 18 provided adjusted effect estimates that were used to calculate pooled relative risks. Among HCV-infected persons, SVR was associated with reduced risk for HCC (relative risk for all persons, 0.24 [95% CI, 0.18 to 0.31], moderate-quality evidence; advanced liver disease hazard ratio, 0.23 [CI, 0.16 to 0.35], moderate-quality evidence).&lt;div class="boxTitle"&gt;Limitation:&lt;/div&gt;In the meta-analyses, some variables could not be controlled for because of the observational design of the included studies.&lt;div class="boxTitle"&gt;Conclusion:&lt;/div&gt;Sustained virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated with reduced HCC. The evidence was determined to be of moderate quality.&lt;div class="boxTitle"&gt;Primary Funding Source:&lt;/div&gt;Centers for Disease Control and Prevention.&lt;/span&gt;</description>
      <guid>http://annals.org/article.aspx?articleID=1657880</guid>
    </item>
  </channel>
</rss>